Sylvester team identifies IL1RAP as target to weaken pancreatic cancer defenses

September 11, 2026 at 05:00 AM2 min

This digest was compiled by AI from multiple sources — links to the originals are below.

Researchers at Sylvester Comprehensive Cancer Center identified IL1RAP as a key receptor that coordinates pancreatic cancer's resistance to treatment. Blocking IL1RAP in preclinical studies reduced immune-suppressive cells, activated T cells, and decreased fibrosis. The team is moving toward a first-of-its-kind neoadjuvant clinical trial combining IL1RAP targeted therapy with chemoimmunotherapy.

Key Facts

The study was published in JCI Insight and led by Jashodeep Datta, M.D., senior author and co-leader of the Gastrointestinal Site Disease Group at Sylvester.
Blocking IL1RAP in preclinical models reduced immune-suppressive cells, increased T cell activity, and decreased fibrosis.
The planned neoadjuvant trial will combine IL1RAP targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery.
Pancreatic tumors depend on neighboring cells and inflammatory signaling to survive and resist therapy, with IL1RAP acting as a shared control point.

IL1RAP Role in Tumor Microenvironment

IL1RAP is a receptor that plays a central role in inflammatory signaling and helps coordinate the network of cells surrounding pancreatic tumors. Pancreatic tumors do not survive on their own; they depend heavily on neighboring cells that help them adapt, grow, and withstand therapy. Because IL1RAP acts as a shared control point for multiple inflammatory signals, blocking it may interfere with a much broader tumor-supporting network. High levels of IL1RAP appear to help maintain both tumor growth and resistance to treatment in the inflamed but immune-suppressed pancreatic cancer microenvironment.

Preclinical Findings and Clinical Translation

In preclinical studies, the Sylvester team found that inhibiting IL1RAP changed the tumor microenvironment in several important ways. Immune-suppressive cells became less abundant, while T cells became more active and better able to function. The tumors also developed less fibrosis and responded more strongly to combination treatment. The work is now moving toward a first-of-its-kind neoadjuvant clinical trial that will combine IL1RAP targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery.